4-(Cyclopropylamino)-2-((4-(4-(Ethylsulfonyl)Piperazin-1-Yl)Phenyl)Amino)Pyrimidine-5-Carboxamide 4-(环丙基氨基)-2-((4-(4-(乙基磺酰基)哌嗪-1-基)苯基)氨基)嘧啶-5-甲酰胺
CAS 1198300-79-6 MFCD298300796
化学结构图
SMILES: CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1
化学属性
| Mol. Weight | 445.54 |
|---|---|
| Appearance | white solid powder |
| Solubility | Soluble in DMSO, not in water |
别名和识别编码
| Chemical Name Translation | 4-(环丙基氨基)-2-((4-(4-(乙基磺酰基)哌嗪-1-基)苯基)氨基)嘧啶-5-甲酰胺 |
|---|---|
| PubChem Substance ID | 44595079 |
| InChI | InChI=1S/C20H27N7O3S/c1-2-31(29,30)27-11-9-26(10-12-27)16-7-5-15(6-8-16)24-20-22-13-17(18(21)28)19(25-20)23-14-3-4-14/h5-8,13-14H,2-4,9-12H2,1H3,(H2,21,28)(H2,22,23,24,25) |
| Synonym | 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide PRT062070 PRT2070; PRT-2070; PRT 2070; PRT062070; PRT 062070; PRT-062070; Cerdulatinib. cerdulatinib |
| Chemical Name | 4-(Cyclopropylamino)-2-((4-(4-(Ethylsulfonyl)Piperazin-1-Yl)Phenyl)Amino)Pyrimidine-5-Carboxamide |
| Formula | C20H27N7O3S |
| IUPAC Name | 4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide |
| InChIKey | BGLPECHZZQDNCD-UHFFFAOYSA-N |
| Canonical SMILES | O=C(C1=CN=C(NC2=CC=C(N3CCN(S(=O)(CC)=O)CC3)C=C2)N=C1NC4CC4)N |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
产品应用
- Cerdulatinib, also known as PRT2070 and PRT062070, is a n ovel, oral, dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor. Cerdulatinib preferentially inhibited JAK1 and JAK3 dependent cytokine mediated signaling and functional responses in various cell types. IL2 mediated STAT5 Y694 was inhibited with an IC50 of 0.27μM, while IL4 mediated signaling to STAT6 Y641 and functional responses in B cells and monocytes, namely CD69, CD25, and CD23 up-regulation, were inhibited with IC50Â’s within the range of 0.11μM to 0.57μM. It is currently being studied in patients with genetically-defined hematologic cancers, as well as for patients who have failed therapy due to relapse or acquired mutations.
